Shots:

• The company has decided to discontinue the development of BCX9930 (500mg, BID) after determining that it is not likely to be commercially competitive in PNH. The company now focuses on the earlier stage asset, BCX10013 which is currently in clinical development & preliminary data from healthy volunteers is expected in Q1’23
• The US FDA partially suspended 3 clinical trials in April involving BCX9930 due to reports of elevated serum creatinine levels in PNH patients participating in the (REDEEM) trial
• Patients in clinical trials benefitting from BCX9930 can continue treatment. As the program advances, the company plans to switch these patients from BCX9930 to BCX10013

Ref: Eisai | Image: Eisai